Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises & Experts

通过生态系统、企业增加 IDeA 州生物医学创业精神

• 批准号: 10761120
• 负责人: Julius N. Korley
• 金额: $ 27.36万
• 依托单位: INSITEHUB LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-21 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10761120
• 关键词: Address; Area; Award; Basic Science; Biological Models; Biomedical Research; Biotechnology; Businesses; Cessation of life; Chemistry; Critical Pathways; Data; Delaware; Development; Disclosure; Ecosystem; Education; Educational Curriculum; Engineering; Ensure; Entrepreneurship; Evaluation; Exposure to; Failure; Funding; Goals; Institution; Intervention; Interview; Knowledge; Learning; Legal patent; Licensing; Marketing; Measures; Medical; Medical Technology; Mentors; Methodology; Modeling; Monitor; National Institute of General Medical Sciences; Participant; Pathway interactions; Patients; Performance; Pharmacologic Substance; Phase; Phase Transition; Price; Private Sector; Process; Program Evaluation; Readiness; Request for Proposals; Resources; Science; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Technology; Technology Transfer; Testing; Training; Translating; Universities; Voice; Work; cohort; commercialization; experience; ideation; improved; innovation; innovative technologies; insight; invention; new technology; online course; outreach; product development; programs; prototype; research study; success; technology development; trend; validation studies

Summary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer interviews regarding challenges to the commercialization of biomedical innovations, there are 3 main barriers to translating basic science products that benefit patients, 1) gap in funding between basic research and validation studies required for early-stage development, 2) lack of knowledge and understanding by innovators about how technologies are brought to market, and 3) lack of access to sufficient technology development and commercialization resources. The creation of the IDeA state program is clear evidence of the need for resources not only to cultivate biomedical research but to spur on commercialization of the new technology created. Correctly identifying deficiencies in the commercialization pathway and preemptively providing corrective measures will create better entrepreneurs and increase the likelihood of commercialization. Our team will develop a rigorous and engaging online curriculum to support the goals and bridge the gap of sufficient training and knowledge for innovators through a high-availability, scalable, on-demand platform. The platform will help both new and experienced innovators to focus on areas of need and provide direct learning interventions from ideation, to market assessment, and go- to-market strategies and will allow for live mentoring and coaching interactions online to support and supplement the curriculum. Data and advanced insights will be analyzed for both the overall program and the learning process that will yield trends as to the correlation between innovators who are deemed successful and the parts of the program leveraged most, allowing us to continuously improve the program. This will result in a more robust education, an increase in the number of biomedical entrepreneurs, an increase in the number of biomedical startups developing market-driven technologies applying for SBIR/STTR and accessing existing ecosystem resources, and increased connectivity between innovative technologies and other enterprises and experts. The specific aims align participants and establish the DE iRED organization with deliverables that include team governance criteria and processes, and innovator roadmaps for Delaware, Northeast, and wider region/IDeA states.They also include the launch of final program and outreach campaigns (local > northeast) and programming using data obtained through pilot activities, testing the revenue model and pricing for sustainability as well as increased reach of the launch outreach campaign to the Northeast and national venue.

总结 拟议的DE iRED计划由大学和私营部门合作伙伴组成， 一个全面的计划，将在技术的早期阶段参与和支持生物医学创新者 通过解决启动过程中的关键瓶颈，实现商业化， 驱动加速器中心根据DRIVEN的客户之声采访， 生物医学创新的商业化，翻译基础科学产品有3个主要障碍 1）基础研究和早期阶段所需的验证研究之间的资金缺口 2）创新者缺乏关于技术如何被带到 市场，以及3）缺乏获得足够的技术开发和商业化资源的途径。的 创建IDEA国家计划清楚地证明了不仅需要资源来培养生物医学， 研究，而是为了刺激所创造的新技术的商业化。正确识别缺陷 商业化途径和先发制人地提供纠正措施将创造更好的企业家 增加商业化的可能性。我们的团队将制定一个严格的和从事在线 课程，以支持目标和桥梁的差距差距足够的培训和知识的创新者通过一个 高可用性、可扩展、按需平台。该平台将帮助新的和有经验的创新者， 关注需求领域，提供从构思到市场评估的直接学习干预措施， 市场战略，并将允许在线实时指导和辅导互动，以支持和补充 课程数据和先进的见解将被分析的整体计划和学习 一个过程，将产生的趋势之间的相关性创新谁被认为是成功的和部分 的计划杠杆最多，使我们能够不断改善该计划。这将导致更强大的 教育，生物医学企业家数量的增加，生物医学企业家数量的增加， 开发市场驱动技术的初创公司申请SBIR/STTR并访问现有生态系统 资源，并加强创新技术与其他企业和专家之间的联系。 具体目标使参与者保持一致，并建立具有可交付成果的DE iRED组织，包括 团队治理标准和流程，以及特拉华州、东北部和更广泛地区的创新者路线图 区域/IDEA州。它们还包括启动最终计划和推广活动（当地>东北部） 使用通过试点活动获得的数据进行编程，测试收入模式和定价， 可持续性以及扩大东北部和国家场地的启动外联活动的范围。